The Optimal Vaccination Strategy to Control COVID-19: A Modeling Study Based on the Transmission Scenario in Wuhan City, China
Zeyu Zhao,Yan Niu,Li Luo,Qingqing Hu,Tianlong Yang,Meijie Chu,Qiuping Chen,Zhao Lei,Jia Rui,Shengnan Lin,Yao Wang,Jingwen Xu,Yuanzhao Zhu,Xingchun Liu,Meng Yang,Jiefeng Huang,Weikang Liu,Bin Deng,Чан Лю,Zhuoyang Li,Peihua Li,Yanhua Su,Benhua Zhao,Roger Frutos,Tianmu Chen
DOI: https://doi.org/10.2139/ssrn.3719045
2020-01-01
SSRN Electronic Journal
Abstract:Background: The optimal vaccination is an essential public health strategy to control the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aims to simulate the optimal vaccination strategy to control the virus epidemic by developing an age-specific model based on the transmission of coronavirus disease 2019 (COVID-19) in Wuhan City, China.Methods: An age-specific mathematical model based on the data of COVID-19 cases in Wuhan City from December 2, 2019 to March 16, 2020 was developed, with two scenarios for controlling transmission and reducing severity to estimate the effectiveness of SARS-CoV-2 vaccination strategy.Findings: Before the lockdown of the Wuhan City, the highest transmissibility of SARS-CoV-2 was among 14-44 years old (effective reproduction number, Reff = 4·28), followed by 14-44 to 45-64 years old (Reff = 2·61), and 14-44 to ≥ 65 years old (Reff = 1·69). We found that the first priority for controlling transmission should be to vaccinate nearly 90% individuals of 14-44 years old, followed by 90% individuals of 45-64 years old. However, the optimal vaccination strategy for reducing severity defined individuals ≥ 65 years old in vaccination priority groups, followed by 14-44 years old groups.Interpretation: The scenario analyses suggested that the optimal vaccination strategy aimed at controlling the transmission of COVID-19 might be to vaccinate about 90% of 15-44 years old individuals; while for reducing severity, the vaccination priority should focus on the older population. Furthermore, we also presented evidence about the heterogeneity of age-specific transmission and vaccination in different areas.Funding Statement: Bill & Melinda Gates Foundation, and the Science and Technology Program of Fujian Province.Declaration of Interests: The authors declare no competing interests.